

The authors thank Professor V. T. Ramakrishnan and P. Murugan for providing the sample for X-ray study.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: BK1361). Services for accessing these data are described at the back of the journal.

References

- Acheson, R. M. (1956). In *Acridines*, 1st ed. London: Arnold Press.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
- Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
- Hempel, A., Hall, S. E., Ledochowska, M. B. & Dauter, Z. (1979). *Acta Cryst.* **B35**, 474–476.
- Lerman, L. S. (1961). *J. Mol. Biol.* **3**, 18–30.
- Murugan, P. & Ramakrishnan, V. T. (1997). Personal communication.
- Nardelli, M. (1983). *Comput. Chem.* **7**, 95–98.
- Nardelli, M. (1991). *PARSTCIF. Program for Creating a CIF from the Output of PARST*. University of Parma, Italy.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Selladurai, S., Subramanian, K. & Ramakrishnan, V. T. (1990). *J. Crystallogr. Spectrosc. Res.* **20**, 227–232.
- Sheldrick, G. M. (1985). *SHELXS86. Program for the Solution of Crystal Structures*. University of Göttingen, Germany.
- Sheldrick, G. M. (1993). *SHELXL93. Program for the Refinement of Crystal Structures*. University of Göttingen, Germany.
- Sivaraman, J., Subramanian, K., Velmurugan, D., Subramanian, E. & Shanmugasundram, P. S. (1996). *Acta Cryst.* **C52**, 481–483.
- Zsolnai, L. (1997). *ZORTEP. An Interactive ORTEP Program*. University of Heidelberg, Germany.

Acta Cryst. (1998). **C54**, 959–961

1,3,4,8-Tetraphenyl-7-oxa-1,2-diazaspiro-[4.4]nona-2,8-dien-6-one†

K. PUVIARASAN,^a L. GOVINDASAMY,^a D. VELMURUGAN,^a
S. SHANMUGA SUNDARA RAJ,^a HOONG-KUN FUN,^b
M. SHANMUGA SUNDARAM^c AND R. RAGHUNATHAN^c

^a*Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India,*

^b*X-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia, and*

^c*Department of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India. E-mail: crystal@giasmd01.vsnl.net.in*

(Received 22 September 1997; accepted 23 December 1997)


Abstract

In the title compound, C₃₀H₂₂N₂O₂, the pyrazoline ring conformation deviates slightly from an ideal envelope conformation. It is substituted by three planar phenyl rings, inclined to it at angles of 89.8 (1), 14.1 (1) and

7.3 (1)°. The substituted phenyl rings are in equatorial and axial positions with respect to the pyrazoline ring. The lactone ring is essentially planar, but the keto group O atom deviates from the least-squares plane through the ring atoms by –0.130 (1) Å. The lactone ring has one phenyl substituent, which adopts an axial position and is inclined at an angle of 11.3 (1)°. The dihedral angle between the pyrazoline and lactone rings is 87.6 (1)°. The crystal structure is stabilized by weak intermolecular hydrogen bonds.

Comment

Pyrazoline compounds have many important pharmacological properties, finding use as, for example, anti-inflammatory agents, herbicides, analgetic agents, antibacterial agents, moderate non-toxic local anaesthetics and antifungal agents (Gusar *et al.*, 1995; Sharma *et al.*, 1993; Ankiwala & Hathi, 1996). They are also effective scintillation solutes and lubricating oil antioxidants (Behar *et al.*, 1967). Lactones serve as starting materials for the synthesis of natural products (Rao, 1976). The lactone derivatives α - and β -angelica lactones are cardiovascular agents, whereas the γ -lactone is used in the perfume industry (Rao, 1964; Jenkins & Hartung, 1950). Furthermore, lactones find use in the preparation of pyrrolidone (Lakhrissi & Chapleur, 1994). In view of the above importance of such compounds and to confirm the structure assignments and relative stereochemistries, a structure determination of the title spiro pyrazoline–lactone compound, (I), was carried out.



In the pyrazoline–lactone ring system (Fig. 1), the pyrazoline ring deviates slightly from an ideal envelope conformation [$Q_2 = 0.238 (2) \text{ \AA}$ and $\Phi_2 = 3.2 (4)^\circ$; Cremer & Pople, 1975]. This is also confirmed by the sum of the bond angles within the pyrazoline ring [534.1 (11)°]. The pyrazoline and lactone rings are nearly orthogonal to each other [87.6 (1)°]. The bond lengths and angles of the pyrazoline ring differ slightly from the values found for acetone 4,4-dimethyl-5-oxo-2-pyrazolin-3-ylhydrazone (Meyers *et al.*, 1996). The three phenyl rings, A, C and D, attached to the pyrazoline ring at C7, N4 and C6, subtend angles of 89.8 (1), 14.1 (1) and 7.3 (1)°, respectively. Phenyl rings A and C are disposed equatorially, while ring D is in an axial position with respect to the pyrazoline ring. The planar lactone ring is inclined at an angle of 11.3 (1)° to the substituted phenyl ring B, which adopts an axial

† DCB contribution No. 882.

position. The O2 atom deviates by $-0.130(1)$ Å from the mean plane of the other five atoms in the lactone ring. The dihedral angle between phenyl rings are: *A/B* 68.4(1), *B/C* 89.2(1), *C/D* 9.7(1) and *A/D* 84.7(1)°. Phenyl rings *B* and *C* are mutually perpendicular. The crystal structure is stabilized by weak C—H...O and C—H...N intermolecular hydrogen bonds.

Data collection

Siemens P4 diffractometer
 $\theta/2\theta$ scans
 Absorption correction: none
 6113 measured reflections
 5184 independent reflections
 3039 reflections with
 $I > 2\sigma(I)$
 $R_{\text{int}} = 0.020$

$\theta_{\text{max}} = 27.50^\circ$
 $h = -1 \rightarrow 12$
 $k = -12 \rightarrow 13$
 $l = -16 \rightarrow 16$
 3 standard reflections
 every 97 reflections
 intensity variation: <3%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.041$
 $wR(F^2) = 0.114$
 $S = 0.783$
 5184 reflections
 308 parameters
 H atoms: see below
 $w = 1/[\sigma^2(F_o^2) + (0.0708P)^2]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$

$\Delta\rho_{\text{max}} = 0.209 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.146 \text{ e \AA}^{-3}$
 Extinction correction:
 SHELXL97 (Sheldrick,
 1997)
 Extinction coefficient:
 0.020 (2)
 Scattering factors from
 International Tables for
 Crystallography (Vol. C)




Fig. 1. Perspective view of the title molecule with the atom-numbering scheme. Displacement ellipsoids are shown at the 30% probability level.

Experimental

Triethylamine (3.3 mmol) was added to a solution of α -benzylidene- γ -phenyl $\Delta^{\beta\gamma}$ -butenolide (3 mmol) and *N*-phenylbenzhydrazidoyl chloride (3 mmol) in dry chloroform (10 ml). The reaction mixture was stirred at room temperature for 36 h, after which the solution was filtered under reduced pressure to remove triethylamine hydrochloride and solvent. The resulting crude product was purified by column chromatography (hexane–EtOAc, 9:1) and crystallized from methanol (Shanmuga Sundaram & Raghunathan, 1997).

Crystal data

C₃₀H₂₂N₂O₂
 $M_r = 442.50$
 Triclinic
 $P\bar{1}$
 $a = 9.554(1)$ Å
 $b = 10.401(1)$ Å
 $c = 12.999(1)$ Å
 $\alpha = 71.92(1)^\circ$
 $\beta = 70.72(1)^\circ$
 $\gamma = 74.95(1)^\circ$
 $V = 1141.15(18)$ Å³
 $Z = 2$
 $D_x = 1.288$ Mg m⁻³
 D_m not measured

Mo $K\alpha$ radiation
 $\lambda = 0.71073$ Å
 Cell parameters from 39 reflections
 $\theta = 5.38$ – 12.51°
 $\mu = 0.081$ mm⁻¹
 $T = 293(2)$ K
 Square prism
 $0.48 \times 0.34 \times 0.32$ mm
 Colourless

Table 1. Selected geometric parameters (Å, °)

O1—C2	1.3630 (17)	N4—C28	1.413 (2)
O1—C9	1.4181 (16)	N5—C6	1.2826 (19)
O2—C2	1.1894 (17)	C6—C22	1.471 (2)
C2—C3	1.543 (2)	C6—C7	1.5184 (19)
C3—N4	1.4819 (19)	C7—C16	1.516 (2)
C3—C8	1.4927 (19)	C8—C9	1.321 (2)
C3—C7	1.571 (2)	C9—C10	1.460 (2)
N4—N5	1.3944 (16)		
C2—O1—C9	107.93 (11)	C2—C3—C7	109.39 (11)
O2—C2—O1	122.29 (14)	N5—N4—C28	116.39 (12)
O2—C2—C3	128.84 (13)	N5—N4—C3	109.88 (11)
O1—C2—C3	108.87 (11)	C28—N4—C3	124.10 (12)
N4—C3—C8	119.15 (12)	C6—N5—N4	109.78 (12)
N4—C3—C2	111.61 (12)	N5—C6—C22	121.66 (13)
C8—C3—C2	100.73 (11)	N5—C6—C7	113.42 (12)
N4—C3—C7	101.20 (11)	C22—C6—C7	124.84 (13)
C8—C3—C7	114.89 (12)		

Table 2. Hydrogen-bonding geometry (Å, °)

D—H...A	D—H	H...A	D...A	D—H...A
C7—H7...O2 ⁱ	0.98	2.54	3.497 (2)	164
C13—H13...O2 ⁱⁱ	0.93	2.50	3.250 (2)	137
C20—H20...N5 ⁱⁱⁱ	0.93	2.73	3.574 (2)	151
C26—H26...O2 ^{iv}	0.93	2.79	3.570 (2)	142

Symmetry codes: (i) $1-x, 1-y, -z$; (ii) $x, 1+y, z$; (iii) $-x, 1-y, 1-z$; (iv) $x-1, y, z$.

Each H atom was placed geometrically and allowed to ride on its parent atom.

Data collection: XSCANS (Siemens, 1994). Cell refinement: XSCANS. Data reduction: XSCANS. Program(s) used to solve structure: SHELXS97 (Sheldrick, 1990). Program(s) used to refine structure: SHELXL97 (Sheldrick, 1997). Molecular graphics: ZORTEP (Zsolnai, 1997). Software used to prepare material for publication: SHELXL97 and PARST (Nardelli, 1983, 1995).

LG thanks the CSIR, India, for providing the financial assistance in the form of a Senior Research Fellowship.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: BM1201). Services for accessing these data are described at the back of the journal.

References

- Ankhiwala, M. D. & Hathi, M. V. (1996). *Indian J. Heterocycl. Chem.* **5**, 229–230.
- Behr, L. C., Fusco, R. & Jarbose, C. H. (1967). In *The Chemistry of Heterocyclic Compounds*, Vol. 22, Pyrazoles, Pyrazolidines, Indazoles and Condensed Rings. Chichester: Wiley Interscience.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
- Gusar, N. I., Gulko, L. I., Gorodetskova, N. R. & Klebanov, B. M. (1995). *Chem. Abstr.* **122**, 290766f.
- Jenkins, G. L. & Hartung, W. H. (1950). In *The Chemistry of Organic Medicinal Products*, 3rd ed. New York: John Wiley.
- Lakhrissi, M. & Chapleur, Y. (1994). *J. Org. Chem.* **59**, 5752–5757.
- Meyers, C. Y., Lulfi, H. G., Kolb, V. M., Hou, Y. & Robinson, P. D. (1996). *Acta Cryst.* **C52**, 2367–2370.
- Nardelli, M. (1983). *Comput. Chem.* **7**, 95–98.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Rao, Y. S. (1964). *Chem. Rev.* **64**, 353–388.
- Rao, Y. S. (1976). *Chem. Rev.* **76**, 625–693.
- Shanmuga Sundaram, M. & Raghunathan, R. (1997). Personal communication.
- Sharma, S. M., Ojha, A. C. & Manohar, R. (1993). *Indian J. Biochem.* **2**, 63–65.
- Sheldrick, G. M. (1990). *Acta Cryst.* **A46**, 467–473.
- Sheldrick, G. M. (1997). *SHELXL97. Program for the Refinement of Crystal Structures*. University of Göttingen, Germany.
- Siemens (1994). *XSCANS Users Manual*. Version 2.1. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Zsolnai, L. (1997). *ZORTEP. An Interactive ORTEP Program for Structure Illustration*. University of Heidelberg, Germany.

Acta Cryst. (1998). **C54**, 961–963

3-Phenylspiro[bicyclo[2.2.1]hept-5-ene-2,3'-chroman]-4'-one†

K. PUVIARASAN,^a L. GOVINDASAMY,^a D. VELMURUGAN,^a S. SHANMUGA SUNDARA RAJ,^a M. SHANMUGA SUNDARAM,^b R. RAGHUNATHAN^b AND HOONG-KUN FUN^c

^aDepartment of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India, ^bDepartment of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India, and ^cX-ray Crystallography Unit, Department of Physics, Universiti Sains Malaysia, Penang, Malaysia. E-mail: crystal@giasmd01.vsnl.net.in

(Received 26 September 1997; accepted 6 January 1998)

Abstract


The title compound, C₂₁H₁₈O₂, resulted from a Diels–Alder reaction. The chromanone moiety consists of one benzene ring fused with a six-membered heterocyclic ring, which adopts a half-chair conformation. In the bicyclo[2.2.1]heptene (norbornene) unit, the two five-membered rings are in envelope conformations, while the six-membered ring adopts a boat conformation. The

† DCB contribution No. 881.

dihedral angle between the chromanone system and the norbornene six-membered-ring moiety is 54.5(4)°, and that between the norbornene six-membered ring and the phenyl substituent is 68.0(1)°.

Comment

The chromanone part of the title compound, (I), comprising rings A and B in Fig. 1, has useful medicinal properties. Chromanone derivatives dilate the heart



and act as remedies for angina pectoris (Hasegaida, 1967). They also show vasodilating activity on the coronary vascular bed (Nagao *et al.*, 1972). The structural analysis of the title spiro chromanone derivative was performed in order to define the conformation of the 4'-chromanone system with respect to the bicyclo[2.2.1]heptene (norbornene) moiety.




Fig. 1. A perspective view of the title molecule showing displacement ellipsoids drawn at 50% probability and the atomic numbering scheme.

In the chromanone moiety, ring B has a half-chair conformation with Cremer & Pople (1975) parameters $q_2 = 0.392(14)$ Å, $q_3 = -0.285(13)$ Å, $\varphi_2 = 48.3(2)^\circ$, $\theta_2 = 126.0(2)^\circ$ and $Q_T = 0.484(13)$ Å. The O2 atom deviates by 0.162(12) Å from the mean plane of ring B. The boat conformation of the norbornene six-membered